DEFB1 and pancreatic adenocarcinoma: Although the impact of DEFB1 in PAAD has not been proven, its specific deletion as the only innate immune gene with long-term balancing selection and heterozygote advantage promotes the development of kidney and prostate cancers (31, 32).